Ardelyx, Inc.

What they do

Ardelyx commercializes IBSRELA, approved for irritable bowel syndrome with constipation (IBS-C), and XPHOZAH, approved to reduce serum phosphorus in chronic kidney disease patients on dialysis. Both products derive from tenapanor, a minimally absorbed NHE3 inhibitor. The company also develops a next-generation NHE3 inhibitor, RDX10531, currently in IND-enabling studies, and is running a Phase 3 trial (ACCEL) for IBSRELA in chronic idiopathic constipation (CIC).

Revenue drivers

• IBSRELA — Approved for IBS-C; Q2 2026 revenue of $86.2 million, up 33% year-over-year, driven by refills and total prescriptions; full-year 2026 guidance revised to $350–370 million.
• XPHOZAH — Approved for hyperphosphatemia in dialysis patients; Q2 2026 revenue of $31.9 million, up 27% year-over-year, from increased writers and prescriptions; full-year 2026 guidance reiterated at $110–120 million.

Recent performance

Q2 2026 total product revenue was $118.1 million, up 31% year-over-year, a company record. Revenue growth was driven by increased demand for both products, though IBSRELA faced payor utilization management headwinds that lowered revenue below expectations. The company reported cash, equivalents, and short-term investments of $281.8 million as of June 30, 2026, up from $264.7 million at year-end 2025. Operating cash flow remained negative in 2025 at -$42.5 million, and the company posted a net loss of $62.0 million for 2025.

Strategy

Management prioritizes driving IBSRELA growth, maintaining XPHOZAH momentum, advancing pipeline programs, and maintaining a solid financial foundation. For IBSRELA, they are expanding the label to include CIC via the ACCEL Phase 3 trial and multiple pediatric studies, which could add six months of patent life. XPHOZAH long-term guidance was pulled while the company assesses evolving market dynamics, including the recent court ruling on CMS reimbursement classification. The company drew $50 million from its SLR loan in June 2026 for general corporate purposes and is working toward profitability in 2027.

Risks

• Payor utilization management — Increased payor management processes for IBSRELA have reduced revenue below expectations, and the company is actively addressing these dynamics.
• CMS reimbursement setback — The D.C. Circuit affirmed dismissal of the lawsuit against CMS regarding XPHOZAH reimbursement classification, and the company will not pursue further litigation.
• Persistent losses — The company has incurred losses every year since inception and had an accumulated deficit of $946.9 million as of December 31, 2025.
• Dependence on two products — Revenue is concentrated in IBSRELA and XPHOZAH, and any regulatory, competitive, or reimbursement issues with either could materially impact results.

Outlook

Management revised full-year 2026 guidance: IBSRELA revenue of $350–370 million, XPHOZAH of $110–120 million, and OPEX below $500 million. They expect to complete ACCEL enrollment by end of 2026 and announce topline data in the second half of 2027. The company reiterates long-term $1 billion IBSRELA revenue goal but is evaluating timing; XPHOZAH long-term guidance was withdrawn pending market dynamics reassessment.